Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "leukemia" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 47
Tytuł:
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Autorzy:
Styczyński, Jan
Wysocki, Mariusz
Dębski, Robert
Kurylak, Andrzej
Balwierz, Walentyna
Rokicka-Milewska, Roma
Matysiak, Michał
Balcerska, Anna
Kowalczyk, Jerzy
Wachowiak, Jacek
Sońta-Jakimczyk, Danuta
Chybicka, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1043814.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
P-glycoprotein
acute myeloblastic leukemia
anthracyclines
acute lymphoblastic leukemia
drug resistance
Opis:
Uptake and efflux of two anthracyclines, idarubicin (IDA) and daunorubicin (DNR), was studied in childhood acute leukemia samples. A comparison of IDA and DNR transport phenomena in relation to drug cytotoxicity and expression of P-glycoprotein (PGP) was made. Intracellular content of IDA/DNR was determined by flow cytometry using the fluorescent properties of the drugs. In vitro drug cytotoxicity was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. PGP expression was analysed by flow cytometry. The uptake and efflux rates were non-significantly higher for IDA than DNR. There were no differences between three types of leukemia with respect to drug content during accumulation and retention. After correction for the cell volume, intracellular concentration of both drugs in each moment of uptake and efflux was significantly lower in relapsed ALL and AML samples in comparison with initial ALL cells. Efflux, but not uptake, of both drugs was inversely correlated with PGP expression and IDA, but not DNR, cytotoxicity. The cytotoxicity was correlated with drug accumulation for both drugs and with drug retention for IDA. In conclusion, it seems that (1) intracellular content was related to the lipophilic properties of the drugs rather than to the type of leukemia, (2) decreased intracellular concentration of both drugs might have an impact on compromised therapy results in AML and relapsed ALL children, (3) IDA presents higher cytotoxicity, which possibly might be decreased by the presence of PGP. These results might have a practical impact on the rational design of new chemotherapy protocols.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 99-107
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cytotoxic effect of nitric oxide on human hematological malignant cells.
Autorzy:
Tsumori, Michihiro
Tanaka, Junko
Koshimura, Kunio
Kawaguchi, Mikiko
Murakami, Yoshio
Kato, Yuzuru
Powiązania:
https://bibliotekanauki.pl/articles/1043819.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
lymphoma
myeloma
leukemia
nitric oxide
Opis:
We investigated the cytotoxic effect of nitric oxide (NO) on primary culture of human hematological malignant cells. Sodium nitroprusside (SNP), an NO donor, had cytotoxic effects on the cells of some patients with malignant lymphoma (ML), acute myelocytic leukemia (AML) or chronic myelomonocytic leukemia (CMMoL), but not with multiple myeloma. Cultured cells from the ML patient remained sensitive to SNP after the cells became resistant to anti-cancer drugs. In contrast, the cells from the patients with AML and CMMoL became resistant to SNP while anti-cancer drugs remained effective. In samples of the cells of the patients with ML and AML, the number of CD3 positive lymphoma cell was decreased by SNP and the number of CD33 negative cells and normal B lymphocytes (CD19 positive cells) were increased. In the cells of the patient with ML, apoptosis was induced by SNP. SNP had no effect on lymphocytes of healthy volunteers. These results suggest that SNP had an anti-tumor effect on human hematological malignant cells.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 139-144
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Preliminary crystallographic studies of Y25F mutant of periplasmic Escherichia coli L-asparaginase.
Autorzy:
Kozak, Maciej
Jaskólski, Mariusz
Röhm, Klaus
Powiązania:
https://bibliotekanauki.pl/articles/1044330.pdf
Data publikacji:
2000
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
protein crystallography
mutagenesis
leukemia
amidohydrolase
Opis:
Periplasmic Escherichia coli L-asparaginase II with Y25F mutation in the active-site cavity has been obtained by recombinant techniques. The protein was crystallized in a new hexagonal form (P6522). Single crystals of this polymorph, suitable for X-ray diffraction, were obtained by vapor diffusion using 2-methyl-2,4-pentanediol as precipitant (pH 4.8). The crystals are characterized by a = 81.0, c = 341.1 Å and diffract to 2.45 Å resolution. The asymmetric unit contains two protein molecules arranged into an AB dimer. The physiologically relevant ABA'B' homotetramer is generated by the action of the crystallographic 2-fold axis along [1, -1, 0]. Kinetic studies show that the loss of the phenolic hydroxyl group at position 25 brought about by the replacement of Y with F strongly impairs kcat without significantly affecting Km.
Źródło:
Acta Biochimica Polonica; 2000, 47, 3; 807-814
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Nursing care of a child with acute lymphoblastic leukemia
Autorzy:
Ślifirczyk, A.
Piszcz, P.
Ślifirczyk, M.
Michalczuk, T.
Urbańczuk, M.
Celiński, M.
Bytys, M.
Domańska, D.
Nikoniuk, M.
Powiązania:
https://bibliotekanauki.pl/articles/1918640.pdf
Data publikacji:
2018
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Acute lymphoblastic leukemia
cancer
care
Opis:
Every year a very large number of children in the world suffer from acute lymphoblastic leukemia, and for years there has been a steady increase in the number of new cases. Acute lymphoblastic leukemia accounts for 75% of leukemia cases in the world. Lymphoblastic leukemia is a cancer disease that originates in B or T cell lymphocytes, which expansion takes place in blood and in the bone marrow. The etiology of the disease is not fully understood because it consists of several factors conditioning its formation. The most important element is the early detection and taking actions resulting in effective disease control through treatment and care of the patient. The nursing process should allow the patient to be involved in and accept the ongoing cancer process, and medical personnel, family and specialists in such fields as psychology and psychiatry should participate.
Źródło:
Progress in Health Sciences; 2018, 8(2); 168-173
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Opposite changes of regulatory T cell blood content may differentially contribute to atherosclerosis or lymphoproliferative disorders
Autorzy:
Pylaeva, Ekaterina
Potekhina, Aleksandra
Pogorelova, Olga
Tripoten, Maria
Balakhonova, Tatiana
Filatova, Anastasia
Klesareva, Elena
Afanasieva, Olga
Noeva, Elena
Arefieva, Tatiana
Powiązania:
https://bibliotekanauki.pl/articles/1064986.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
B-cell chronic lymphocytic leukemia
Opis:
Background. Chronic autoimmune inflammation in arterial wall may lead to atherosclerosis progression. Objective. The aim of this study was to investigate the association between Treg, Th17 and B1a cell blood frequencies as well as IgM autoantibodies to oxLDL and the abundance of carotid atherosclerosis. Material and methods. 18 patients with increased IMT (intima-media thickness) and 65 patients with different severity of carotid atherosclerotic plaques were included. Treg, Th17 and B1a cell blood frequencies were assessed via direct immunofluorescence staining and flow cytometry, oxLDL as well as IgM autoantibodies to oxLDL were measured with commercial kits. Results. We observed higher values of Treg in patients without carotid atherosclerosis. Patients with intact carotid arteries as compared to patients with mild atherosclerotic plaques had decreased Th1 levels. OxLDL IgM levels were higher in patients with intact carotid arteries. Patients who received statin treatment had higher levels of Treg. Immunophenotyping of B cells revealed two cases of monoclonal B-cell lymphocytosis and 1 case of B-CLL (B-cell chronic lymphocytic leukemia) in elderly patients with intact carotid arteries. Conclusion. We hypothesize that certain parameters of cell immunity may hamper atherosclerosis while protecting from lymphoproliferative disorders.
Źródło:
OncoReview; 2016, 6, 1; A29-36
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Monocytes in children with leukemias and lymphomas - down-regulation of HLA and costimulatory molecules.
Autorzy:
Łuczyński, Włodzimierz
Stasiak-Barmuta, Anna
Krawczuk-Rybak, Maryna
Szymański, Marcin
Malinowska, Iwona
Mitura-Lesiuk, Małgorzata
Powiązania:
https://bibliotekanauki.pl/articles/1041525.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
infection
lymphoma
costimulation
leukemia
monocytes
Opis:
The aim of the study was to evaluate the function of monocytes in children with leukemias and lymphomas based on the expression of critical costimulatory, activatory and adhesion molecules (CD80, CD86, HLA-DR and CD54 = ICAM-1), estimated with tricolor flow cytometry. In comparison to the control group we found a lower percentage of monocytes with costimulatory molecules (CD80 before and CD86 after lipopolysaccharide stimulation) at the time of diagnosis and of monocytes with HLA-DR molecules after remission induction. We also noted a lower percentage of monocytes with HLA-DR expression in the group with severe or therapy resistant infections. The results of our investigation suggest some defect in costimulation and antigen presentation in lymphoproliferative diseases in children.
Źródło:
Acta Biochimica Polonica; 2004, 51, 4; 1067-1073
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
In vitro activity of oxazaphosphorines in childhood acute leukemia: Preliminary report.
Autorzy:
Styczyński, Jan
Wysocki, Mariusz
Dębski, Robert
Balwierz, Walentyna
Rokicka-Milewska, Roma
Matysiak, Michał
Balcerska, Anna
Kowalczyk, Jerzy
Wachowiak, Jacek
Sońta-Jakimczyk, Danuta
Chybicka, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1043830.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
ALL
leukemia
sensitivity
glufosfamide
resistance
Opis:
Glufosfamide (β-D-glucosyl-ifosfamide mustard) is a new agent for cancer chemotherapy. Its pharmacology is similar to commonly used oxazaphosphorines, but it does not require activation by hepatic cytochrome P-450 and preclinically demonstrates lower nephrotoxicity and myelosuppression than ifosfamide. The aim of the study was a comparison of the drug resistance profiles of glufosfamide and other oxazaphosphorines in childhood acute leukemias. Leukemic cells, taken from children with ALL on diagnosis (n = 41), ALL on relapse (n = 12) and AML on diagnosis (n= 13) were analyzed by means of the MTT assay. The following drugs were tested: glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and mafosfamide cyclohexylamine salt (MAF). In the group of initial ALL samples median cytotoxicity values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8 μM, respectively. In comparison with initial ALL samples, the relative resistance for GLU and IFO in relapsed ALL samples was 1.9 (p = 0.049) and 1.3 (ns), and in initial AML samples 31 (p < 0.001) and 5 (p = 0.001), respectively. All oxazaphosphorines presented highly significant cross-resistance. Glufosfamide presented high activity against lymphoblasts both on diagnosis and on relapse.
Źródło:
Acta Biochimica Polonica; 2002, 49, 1; 221-225
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Myeloid sarcoma associated with blast crisis in chronic myelogenous leukemia - case report
Autorzy:
Szymczyk, Agnieszka
Podhorecka, Monika
Tomczak, Waldemar
Szumiło, Justyna
Hus, Marek
Powiązania:
https://bibliotekanauki.pl/articles/972387.pdf
Data publikacji:
2016
Wydawca:
Instytut Medycyny Wsi
Tematy:
myeloid sarcoma
chronic myelogenous leukemia
blast crisis
Opis:
Introduction. Myeloid sarcoma (MS) is a rare extramedullary tumour which may precede or occur concomitantly with bone marrow involvement in acute myeloid leukemia, myelodysplastic syndrome, or blast crisis in chronic myeloproliferative disorder. Myeloid sarcoma is most commonly found in lymph nodes, skin, subcutaneous tissue and gums, while it is less common in bones, the retroperitoneal space and eye socket. Case Report. The case is reported of a 65-year-old woman with chronic myelogenous leukemia treated for about 20 years with hydroxyurea, 6-mercaptopurine and tyrosine-kinase inhibitors. During the treatment, the general condition of the patient progressively deteriorated, lymphadenopathy and splenomegaly worsened, and blast crisis was diagnosed. After the first cycle of induction chemotherapy, the patient’s lymph nodes were swollen and painful. One of the lymph nodes was subjected to histopathology, on the basis of which a diagnosis of MS was made. As the patient showed no response to the treatment, palliative care was initiated. Three months after the diagnosis of MS, the disease progressed. The patient died of infectious complications. Conclusions: A diagnosis of MS, which is considered an adverse prognostic factor, significantly reduces the chances of remission and overall survival in patients with acute myelogenous leukemia or blast crisis inchronic myeloproliferative disorders. It seems that early confirmation of the diagnosis and initiation of the treatment adjusted to the patient’s clinical condition may improve the prognosis and increase the response rates.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2016, 10, 2; 136-139
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Kowal, M.
Nogalski, A.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2081565.pdf
Data publikacji:
2018
Wydawca:
Instytut Medycyny Wsi
Tematy:
chronic lymphocytic leukemia
ofatumumab
monoclonal antibodies
immunotherapy
Opis:
Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL) treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland, during 2011–2013. Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy. Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3 patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and an infection with Candida glabrata were observed. Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
Źródło:
Annals of Agricultural and Environmental Medicine; 2018, 25, 1; 56-59
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells
Autorzy:
Wu, Yao-Hui
You, Yong
Chen, Zhi-Chao
Zou, Ping
Powiązania:
https://bibliotekanauki.pl/articles/1040668.pdf
Data publikacji:
2008
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
chemotherapeutic resistance
Survivin
acute myeloid leukemia
shRNA
apoptosis
Opis:
The role of Survivin in the pathogenesis of leukemia was explored in order to discover the effective avenues for gene therapy. Most primary leukemia cells isolated from patients as well as three leukemia cell lines (HL-60, K562, and U937) all expressed Survivin gene. To investigate the relationship between Survivin and chemotherapeutic resistance, HL-60 cells were treated with daunorubicin (DNR), mitoxantrone (MIT) or arsenious oxide (As2O3), and it was found that after 24 h the level of Survivin mRNA was decreased by 9.7%, 41.0% and 27.5%, respectively. At 72 h, the level of Survivin mRNA was increased by 21.2% and 65.2% in HL-60 cells treated with DNR or MIT, but decreased by 33.2% in those treated with As2O3 as compared with that in the cells treated for 24 h. These results showed that DNR and MIT could initally decrease the expression of Survivin and then increase it, but As2O3 could decrease the Survivin expression continually. Furthermore, shRNA plasmids targeting the Survivin gene (pEGFP-Survivin), which can silence the expression of Survivin with a high specificity, were constructed. pEGFP-Survivin and pEGFP-H1 were transfected into HL-60 cells via electroporation and selected by G418, and HL-60/Survivin and HL-60/EGFP cells were obtained. After treatment with DNR, the cell survival rate and IC50 of DNR in HL-60/Survivin cells were decreased substantially as compared with those of HL-60/EGFP and HL-60 cells (IC50 of DNR: 18.3 ± 2.45 vs 40.8 ± 6.37 and 39.2 ± 5.91 ng/ml, respectively), and the apoptosis rate was elevated ((84.3 ± 19.7)% vs (45.8 ± 13.8)% and (50.9 ± 12.4)%, respectively). These results suggest that shRNA can down-regulate the expression of Survivin in HL-60 cells substantially and improve their sensitivity to DNR. They also further explain the pathogenesis of leukemia drug resistance and provide new theory in the design of clinical therapies.
Źródło:
Acta Biochimica Polonica; 2008, 55, 4; 673-680
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Partial remission in patient with Richter syndrome: an „emergency” treatment with pixantrone
Autorzy:
Szwedyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1035640.pdf
Data publikacji:
2020-06-30
Wydawca:
Medical Education
Tematy:
Richter syndrome
chemotherapy
chronic lymphocytic leukemia
immunotherapy
pixantrone
Opis:
Chronic lymphocytic leukemia is the most commonly recognized type of leukemia in adults. The appearance of systemic symptoms such as weight loss, fever, or local symptoms in the form of rapidly growing organomegaly, lymphadenopathy in a patient with CLL raises the suspicion of transformation into a high-grade lymphoma – defined as Richter syndrome which is usually associated with very poor prognosis. The described case concerns a 71-year-old patient with this diagnosis, in whom due to the confirmed resistance to subsequent lines of immuno- and chemotherapy, an „emergency” treatment with a modern chemotherapy drug from the aza-anthracendion group – pixantrone was used. Treatment with pixantrone was associated with a relatively good response, translating into partial remission (also in the area of infiltrative changes in the head and neck structures), stabilization of the course of the disease and, consequently, allowed to extend the patient’s life.
Źródło:
OncoReview; 2020, 10, 2; 52-56
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system
Autorzy:
Sacha, Tomasz
Góra-Tybor, Joanna
Szmit, Sebastian
Powiązania:
https://bibliotekanauki.pl/articles/1035757.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
cardiovascular toxicity
chronic myeloid leukemia
tyrosine kinase inhibitors
Opis:
The use of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia has significantly improved the prognosis and outcomes for most patients. Clinical trials indicate that long-term CML therapy requires the introduction of second- or third-generation inhibitors in approximately 40–50% of cases. Effective in the case of imatinib resistance or intolerance, second generation TKI’s can also be used as a first-line treatment, leading to a faster, and deeper molecular response. TKIs, however, have also been observed to cause significant late adverse effects, including cardiovascular complications, which may raise certain safety concerns. The excellent treatment outcomes achieved with tyrosine kinase inhibitors have led to a gradual increase in the number and age of treated patients, and the associated higher incidence and severity of age-related co-morbidities such as diabetes, hypercholesterolemia, atherosclerosis, ischemic heart disease, hypertension, and congestive heart failure, which raise the risk of treatment-related cardiovascular complications. The article discusses the effects of individual TKIs on the pathogenesis of cardiovascular complications and presents the results of clinical trials that studied their impact on the incidence of such events.
Źródło:
OncoReview; 2019, 9, 1; 3-21
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The role of residence near hazardous waste sites containing benzene in the development of hematologic cancers in upstate New York
Autorzy:
Boberg, Erik
Lessner, Lawrence
Carpenter, David O.
Powiązania:
https://bibliotekanauki.pl/articles/2185371.pdf
Data publikacji:
2011-12-01
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
environmental exposure
lymphoma
Leukemia
ecological study
ethnic difference
Opis:
Objectives: Epidemiologic studies suggest an association between environmental exposure to benzene and hematologic cancers, but the relationship is not fi rmly established. The aim of this study was to assess the potential association between residence near hazardous waste sites containing benzene and hospitalization discharge rates for persons having hematologic cancers. Materials and Methods: We determined the number of hospital discharges of people with hematologic cancers in New York State except for New York City for the years 1993 to 2008. Descriptive statistics and negative binomial regression models were used to compare the rates of hospitalization of residents in zip codes containing hazardous waste sites containing benzene to the rates of discharges from residents in zip codes without waste sites. Results: When adjusting for potential confounders we found a 15% increase in the rate of hospitalization for chronic lymphatic leukemia (CLL) [rate ratio (RR): 1.15; 95% confi dence interval (CI): 1.00–1.33], a 22% increase in the rate of discharges for total leukemia (RR: 1.22; 95% CI: 1.04–1.43) and a 17% increase in the rate of discharges for total lymphoma (RR: 1.17; 95% CI: 1.02–1.35) in the benzene exposed sites. We found greater effects of exposure in African Americans compared to Caucasians, females compared to males and people with higher socioeconomic status (SES) compared to those with lower SES for several of the diseases studied. Conclusions: After controlling for major confounders we found statistically signifi cant increases in discharge rates for several hematologic cancers in persons residing in zip codes containing benzene waste sites. These results provide additional support for a relationship between environmental exposure to benzene and risk of hematologic cancers.
Źródło:
International Journal of Occupational Medicine and Environmental Health; 2011, 24, 4; 327-338
1232-1087
1896-494X
Pojawia się w:
International Journal of Occupational Medicine and Environmental Health
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Rare case of Richter’s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) - case report and literature
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Szczepanek, D.
Grywalska, E.
Szumiło, J.
Trojanowski, P.
Czabak, O.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2085452.pdf
Data publikacji:
2020
Wydawca:
Instytut Medycyny Wsi
Tematy:
liver
thyroid
chronic lymphocytic leukemia
Richter’s syndrome
Opis:
Richter’s syndrome (RS) is a rare complication in which chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) transforms into a more aggressive type of lymphoma – diffuse large B cell lymphoma (DLBCL), or Hodgkin’s lymphoma (HL). The review describes the clinical case of a patient with CLL and RS diagnosis. A computed tomography (CT) scan of the abdominal cavity detected numerous normodense areas in the liver. Simultaneously, ultrasound examination (USG) of the thyroid revealed the presence of a solid hypoechogenic lump. The material sampled from closed biopsies of liver and thyroid in both cases allowed the diagnosis of diffuse large B cell lymphoma (DLBCL). The liver and the thyroid are particularly rare locations of RS. However, those cases allowed the conclusion that RS may occur even in a very unexpected and less probable location.
Źródło:
Annals of Agricultural and Environmental Medicine; 2020, 27, 1; 160-164
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Mucormycosis in a patient with acute myeloblastic leukemia following liver transplantation for Wilson’s disease
Autorzy:
Łanocha, A.A.
Guzicka-Kazimierczak, R.
Zdziarska, B.
Wawrzynowicz-Syczewska, M.
Powiązania:
https://bibliotekanauki.pl/articles/2085182.pdf
Data publikacji:
2019
Wydawca:
Instytut Medycyny Wsi
Tematy:
Mucormycosis
acute myeloblastic leukemia
Willson’s disease
liver transplantation
Opis:
A case is presented of mucormycosis in a patient with acute myeloblastic leukemia following liver transplantation for Wilson’s disease. A 58-year-old female was admitted to the Department of Haematology with deterioration of her general condition, loss of appetite, tiredness and difficulty with mental contact for a few days. Blood and urine cultures for bacteria and fungus, galactomannan antigen were negative. Whole body computed tomography demonstrated bilateral hilar lymphadenopathy with necrotic lesions: splenomegaly with a hypodensive lesion 13 × 20 × 19 mm and lower pulmonary infiltrates suggested fungal etiology. Magnetic resonance imaging of the brain showed thickened meninges. Finally, mucormycosis was diagnosed. Treatment with amphotericin B lipid complex was started, resulting in an partial improvement of the general condition and decreased level of inflammatory markers. However, the patient’s condition continued to deteriorate, with sepsis etiology Escherichia coli, and despite the intensive managements she eventually died.
Źródło:
Annals of Agricultural and Environmental Medicine; 2019, 26, 4; 665-668
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 47

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies